US Patent Issued to Syracuse University on Aug. 12 for "Monomeric peptide multi-agonist targeting the GLP1 receptor and NPY receptors" (New York Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,384,825, issued on Aug. 12, was assigned to Syracuse University (Syracuse, N.Y.).

"Monomeric peptide multi-agonist targeting the GLP1 receptor and NPY receptors" was invented by Robert P. Doyle (Manlius, N.Y.) and Brandon Milliken (Syracuse, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A series of chimeric peptides that provide a mechanism for obesity treatment concomitant with T2DM in the form of dual agonism of the anorectic neuropeptide Y-receptor (Y2-R) and the glucoregulatory receptor GLP1-R. Preliminary results show that, dependent on the selected peptide, once-daily administration suppress FI in male and female rats can be reduced to 12-65...